Trial Information

Summary: A Pilot Study of Arsenic Trioxide in the Treatment of Relapsed and Refractory Indolent Lymphomas

This is a phase II research study investigating arsenic trioxide in low-grade, non-Hodgkin's lymphomas, including CLL. The arsenic trioxide is administered by vein for five consecutive days every four weeks.
No Compensation Provided

Patient Inclusion/Exclusion Criteria:

1. Low-grade lymphomas, including chronic lymphocytic leukemia (CLL), that have recurred after prior therapy.
2. Age 18 and older


1. Concurrent anti-cancer therapy.
2. History of abnormal heart rhythm or heart attack within the past 6 months.

Contact:

Robin Brenner, RN
Mount Sinai Medical Center
One Gustave L. Levy Place

New York, NY 10029
Telephone: 212-241-8617
Fax: 212-289-2663
Email:

If you would like to learn more about participating in this study, please send an e-mail message using the form below.

*Subject:

Name:

Address:

City:

State:

*Zip:

*Country:

Phone:

*Email address:

Message:

Please note: A number of commercial online services display an error message after you click on Send. Please be assured that your message has been received.

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: June 1, 2008 at 5:43:32 AM


Back to Centerwatch Trial Listing by Location


Additional resources
in this illness area

Copyright © 1995 - 2008, CenterWatch
All Rights Reserved

This site was developed in association with Illumina Interactive, Boston, MA